Clinical trials: Staphylococcus Aureus Skin Infection
Staphylococcal Skin Infection
Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus
Study 0017 compares the safety and effectiveness of an investigational drug, telavancin, and an approved drug, vancomycin, for the treatment of complicated skin and skin structure infections.
- Trial name
- ATLAS1 (NCT00091819)
- Testing
- Telavancin, Vancomycin
- Where
- United States
- Volunteers
- 862 people
- Sponsor
- Cumberland Pharmaceuticals
Staphylococcal Skin Infections, Abscesses
Staphylococcus Aureus Decolonization Study
The purpose of this study is to determine whether measures to eliminate the Staph germ from the skin of the index patient (with a special ointment and soap) are more effective when performed by everyone in the household rather…
- Conditions
- Staphylococcal Skin Infections, Abscesses, Furunculosis, Staphylococcus Aureus
- Trial name
- SuDS (NCT00731783)
- Testing
- 2% Mupirocin Ointment, 4% Chlorhexidine liquid soap, Hygiene protocol
- Where
- United States
- Volunteers
- 183 people
- Sponsor
- Washington University School of Medicine
Staphylococcal Skin Infections
Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA
This was a real-world, prospective, open-label, multicenter study in which participants were randomized (1:1) to receive intravenous (IV) vancomycin or IV daptomycin.
- Trial name
- DAPHEOR1006 (NCT01419184)
- Testing
- Daptomycin, Vancomycin
- Where
- 26 sites in United States, Puerto Rico
- Volunteers
- 250 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Staphylococcal Skin Infection
Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus
Study 0018 (NCT00107978) compares the safety and effectiveness of an investigational drug, telavancin, and an approved drug, vancomycin, for the treatment of complicated skin and skin structure infections.
- Trial name
- ATLAS2 (NCT00107978)
- Testing
- Telavancin, Vancomycin
- Where
- United States
- Volunteers
- 1,035 people
- Sponsor
- Cumberland Pharmaceuticals
Abscesses, Furunculosis
The Natural History of Community-Associated MRSA Infections and Decolonization Strategies
The purpose of this study is to determine the natural history of community-associated Staphylococcus aureus infections in both adult and pediatric patients by monitoring the rate of recurrent infections in those colonized with S.
- Conditions
- Abscesses, Furunculosis, Staphylococcus Aureus, Staphylococcal Skin Infections
- Trial name
- StLStaRS (NCT00513799)
- Testing
- Mupirocin ointment, Chlorhexidine showers, Bleach baths (dilute)
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Washington University School of Medicine
Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections
Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA
To determine the safety and descriptive efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections in children, aged birth to 17 years (inclusive), known or suspected to be caused by…
- Conditions
- Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections
- Trial name
- NCT02814916
- Testing
- Dalbavancin, Vancomycin, Oxacillin
- Where
- 84 sites in United States, Argentina and 18 more
- Volunteers
- 199 people
- Sponsor
- AbbVie
Abscess
Emergency Bedside Ultrasound for Pediatric Soft Tissue Infections
The purpose of this study is to determine if soft tissue infections in pediatric patients can be more accurately diagnosed (i.e.
- Trial name
- NCT00595881
- Testing
- Bedside emergency ultrasound
- Where
- United States
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Philadelphia
Staphylococcus Aureus, HIV Infections
Rifabutin Based Therapy for the Eradication of Staphylococcus Aureus Colonization in HIV Infected Adults
DESIGN: This single center, double-blinded, randomized phase II study is being conducted to assess the efficacy of a rifabutin based regimen to eliminate S. aureus colonization in HIV infected individuals.
- Trial name
- NCT00869518
- Testing
- rifabutin plus trimethoprim sulfamethoxazole
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of California, San Francisco
Skin Disease, Bacterial, Abscess
Evaluation of 3 Versus 10 Days of Antibiotics in Skin Abscesses After Surgical Drainage
The objective of this study is to determine if there is a difference in treatment failures and recurrent skin infections when patients are given 3 or 10 days of antibiotics for uncomplicated skin abscesses after they have been…
- Trial name
- NCT02024867
- Testing
- Trimethoprim-Sulfamethoxazole
- Where
- United States
- Volunteers
- 249 people, healthy volunteers welcome
- Sponsor
- Lucy Holmes, MD
Skin Infections, Bacterial
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
The purpose of this study is to provide further evidence of the clinical and bacteriological efficacy of retapamulin in the treatment of subjects with SITL or impetigo due to MRSA.
- Trial name
- NCT00852540
- Testing
- Retpamulin Ointment, 1%, Linezolid
- Where
- 53 sites in United States
- Volunteers
- 410 people
- Sponsor
- Stiefel, a GSK Company
Skin and Subcutaneous Tissue Bacterial Infections, Skin Structures and Soft Tissue Infections
Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections
The purpose of this study is to evaluate the effects of Delafloxacin versus Vancomycin plus Aztreonam in the treatment of patients with acute bacterial skin and soft tissue infections.
- Trial name
- NCT01984684
- Testing
- delafloxacin, vancomycin, aztreonam
- Where
- 94 sites in United States, Argentina and 14 more
- Volunteers
- 850 people
- Sponsor
- Melinta Therapeutics, Inc.
Skin and Subcutaneous Tissue Bacterial Infections, Staphylococcus Aureus
Staph Household Intervention for Eradication (SHINE)
The investigators propose a pragmatic comparative effectiveness trial evaluating several decolonization strategies in patients with Staphylococcus aureus infection, their household contacts, and household environmental surfaces.
- Conditions
- Skin and Subcutaneous Tissue Bacterial Infections, Staphylococcus Aureus, MRSA - Methicillin Resistant Staphylococcus Aureus Infection
- Trial name
- SHINE (NCT02572791)
- Testing
- Chlorhexidine, Mupirocin, Household cleaning
- Where
- 2 sites in United States
- Volunteers
- 835 people
- Sponsor
- Washington University School of Medicine
Staphylococcus Aureus, MRSA Skin Infections
Methicillin-resistant Staphylococcus Aureus (MRSA) Skin and Soft Tissue Infection (SSTI) Prevention in Military Trainees
This cluster-randomized prospective study will evaluate the effect of hygiene-based intervention strategies on the incidence of overall SSTI and MRSA-associated SSTI among military trainees.
- Conditions
- Staphylococcus Aureus, MRSA Skin Infections, Staphylococcal Skin Infections
- Trial name
- NCT01105767
- Testing
- Chlorhexidine gluconate, Supplemental training, education and hygiene
- Where
- United States
- Volunteers
- 30,209 people, healthy volunteers welcome
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Community-Acquired Staphylococcus Aureus
Prevention of Recurrent Infections Caused by Community Acquired Staphylococcus Aureus (CA-SA) in Children
The primary purpose of this study is to determine if adding bleach baths to routine ways for prevention of Staph infections is helpful. The amount added is a very weak amount.
- Trial name
- NCT00901316
- Testing
- Routine Measures Group, Bleach Bath Group (Bleach plus routine measures)
- Where
- 2 sites in United States
- Volunteers
- 987 people
- Sponsor
- Baylor College of Medicine
Abscesses
Prospective Randomized Trial of Bactrim on 7 Day Outcome in Patients With Uncomplicated Abscesses
Patients will be enrolled in a multi-center study to prospectively evaluate outcome after treatment for an uncomplicated skin abscess. All patients will receive incision and drainage and wound cultures.
- Trial name
- NCT00973765
- Testing
- bactrim
- Where
- United States
- Volunteers
- 212 people, healthy volunteers welcome
- Sponsor
- 59th Medical Wing
Skin Diseases, Bacterial, Abscess
Asymptomatic Colonization With S. Aureus After Therapy With Linezolid or Clindamycin for Acute Skin Infections
In this pilot study, the objective is to determine the prevalence of asymptomatic carriage of S. aureus in patients with ABSSSIs and minor cutaneous abscesses after therapy with either linezolid or clindamycin at 40 days after…
- Trial name
- NCT01619410
- Testing
- Linezolid, Clindamycin
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Chicago
Staphylococcal Infection
Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
The purpose of this clinical trial is to evaluate 2 different antibiotics, drugs that fight bacteria, [clindamycin (CLINDA) and trimethoprim-sulfamethoxazole (TMP-SMX)] and wound care for the outpatient management of…
- Trial name
- NCT00730028
- Testing
- Trimethoprim-sulfamethoxazole, Clindamycin
- Where
- 6 sites in United States
- Volunteers
- 1,310 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Infections, Soft Tissue
Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine (GSK3878858A) When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)
The study evaluates the safety, immunogenicity, and efficacy of the GSK S. aureus candidate vaccine (GSK3878858A) when administered to two groups: healthy adults (dose-escalation phase) and adults aged 18 to 64 years with a…
- Trial name
- NCT04420221
- Testing
- Sa-5Ag half dose non-adjuvanted, Sa-5Ag full dose non-adjuvanted, Sa-5Ag half dose adjuvanted
- Volunteers
- 226 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline